Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revance Therapeutics, Inc.RVNC · Entity 83521 | CCO & President, | October 15, 2018 | October 17, 2018 |
| Stablecoin Development CorpNBY · Entity 7283 | Director | May 30, 2019 | October 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revance Therapeutics, Inc.
Report date October 15, 2018 · Filed October 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,407 |
Reported balance
After 2018-10-15 transaction · row 1
1 source rowRow 1 · 2018-10-15 · Tax withholding · Disposed 7,093 · Balance 96,407 F1: Represents the number of shares withheld by and surrendered by Mr. Zavodnick to the Issuer on October 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award ("RSA") for 95,000 shares. The RSA vests in four equal annual installments from October 15, 2017, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by and surrendered by Mr. Zavodnick to the Issuer on October 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award ("RSA") for 95,000 shares. The RSA vests in four equal annual installments from October 15, 2017, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.
Stablecoin Development Corp
Report date May 30, 2019 · Filed October 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2029-05-30 | Direct | 20,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock options will vest in 12 equal monthly installments beginning on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest in 12 equal monthly installments beginning on the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Disposition to issuer · Disposed 99,971 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 99,971 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.89 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Disposition to issuer · Disposed 16,674 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 99,971 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2019 Filed Oct 30, 2019 20:31 UTC | Stablecoin Development Corp NBY · Entity 7283 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001437749-19-020935 · rdgdoc.xml · derivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common stock · 20,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The stock options will vest in 12 equal monthly installments beginning on the grant date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 18:53 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 7,093 | $23.94 | $169,806.42 |
DisclosureSEC source: 0001628280-18-012608 · wf-form4_153981679009475.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · CCO & President, 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,407 F1 · acquired: Represents the number of shares withheld by and surrendered by Mr. Zavodnick to the Issuer on October 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award ("RSA") for 95,000 shares. The RSA vests in four equal annual installments from October 15, 2017, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:22 UTC | Stablecoin Development Corp NBY · Entity 7283 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001437749-18-011213 · rdgdoc.xml · derivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,698 Underlying: common stock · 20,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: Stock options will vest in 12 equal monthly installments. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 21:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $29.15 | $0.00 |
DisclosureSEC source: 0001479290-18-000017 · wf-form4_151822873290802.xml · derivative · entry 2 Zavodnick Todd Erik · CIK 0001660467 · CCO & President, 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2028-02-07 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 8, 2018, subject to Mr. Zavodnick's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 21:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000017 · wf-form4_151822873290802.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · CCO & President, 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,500 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2018, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan(the "Plan")) on each vesting date. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 20:52 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $24.40 | $0.00 |
DisclosureSEC source: 0001209191-17-053533 · doc4.xml · derivative · entry 2 Zavodnick Todd Erik · CIK 0001660467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-17 F2 · derivative.exercise_date: The shares subject to the stock option shall vest over a period of four years commencing September 18, 2017, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Zavodnick's Continuous Service (as defined in the Plan) through each such vesting date. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 20:52 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053533 · doc4.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 F1 · shares: Represents a restricted stock award (the "RSA"). The shares underlying the RSA shall vest over a period of four years commencing October 15, 2017, with 25% vesting each year on the annual anniversary of the vesting commencement date, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's Amended and Restated 2014 Inducement Plan (the "Plan")) through each such vesting date. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:56 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Disposition to issuerStock Option (right to buy) · Derivative | 16,674 | $0.00 Strike: $40.89 | $0.00 |
DisclosureSEC source: 0001209191-17-028628 · doc4.xml · derivative · entry 2 Zavodnick Todd Erik · CIK 0001660467 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,674 shares Expires 2027-01-17 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:56 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Disposition to issuerCommon Stock | 99,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-028628 · doc4.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 99,971 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 99,971 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 11:08 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Tax withholdingCommon Stock | 7,815 | $55.62 | $434,670.30 |
DisclosureSEC source: 0001209191-17-015088 · doc4.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,971 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 24, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on February 1, 2016 for 99,049 shares. The RSUs vest in four equal annual installments beginning February 1, 2016. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:09 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | GrantStock Option (right to buy) · Derivative | 16,674 | $0.00 Strike: $40.89 | $0.00 |
DisclosureSEC source: 0001209191-17-004985 · doc4.xml · derivative · entry 2 Zavodnick Todd Erik · CIK 0001660467 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,674 Underlying: Common Stock · 16,674 shares Expires 2027-01-17 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option vest on January 18, 2018, and the remainder vest in equal monthly installments over a 36-month period thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:09 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | GrantCommon Stock | 8,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-004985 · doc4.xml · nonDerivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,786 F1 · security: Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments, with the vesting commencement date of January 18, 2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:15 UTC | Stablecoin Development Corp NBY · Entity 7283 | Grantstock option (right to buy) · Derivative | 22,359 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001437749-17-000193 · rdgdoc.xml · derivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,699 Underlying: Common Stock · 22,359 shares Expires 2027-01-03 F1 · security: Granted pursuant to the 2007 Omnibus Incentive Plan and the 2017 NonEmployee Director Compensation Plan F2 · derivative.exercise_date: stock options will vest in equal month installments starting on the date of grant Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 22:20 UTC Amendment | Stablecoin Development Corp NBY · Entity 7283 | GrantStock Option (right to buy) · Derivative | 247 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001437749-16-039486 · rdgdoc.xml · derivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,367 Underlying: common stock · 247 shares Expires 2026-10-03 F1 · shares: Amended Form 4 filed to fix the share amount on previous filing. Grant should be in the amount of 247, not 3303. F2 · balance_after: Amended Form 4 to state that total stock options held is 11,340 shares, not 14,396 as previously reported. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:34 UTC | Stablecoin Development Corp NBY · Entity 7283 | GrantStock Option (right to buy) · Derivative | 3,303 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001437749-16-039484 · rdgdoc.xml · derivative · entry 1 Zavodnick Todd Erik · CIK 0001660467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,396 Underlying: common stock · 3,303 shares Expires 2026-10-03 F1 · security: Granted pursuant to the 2007 Omnibus Incentive Plan and the 2016 NonEmployee Director Compensation Plan F2 · derivative.exercise_date: Stock options will vest in equal monthly installments over the remainder of the year starting from the date of grant Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.